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Introduction {#sec1}
============

Innate immune cells challenged with certain stimuli undergo long-lasting changes that result in improved response to a second challenge by the same or different microbial insult, a process referred to as trained immunity ([@bib30]). Stimuli driving trained immunity lead to a shift to aerobic glycolysis ([@bib3]), accompanied by sustained changes in the epigenome, mainly via histone methylation and acetylation ([@bib29]). Among trained immunity inducers, exposure to a low dose of *Candida albicans* or the fungal cell wall component β-glucan protects mice from secondary lethal systemic candidiasis ([@bib8]) or heterologous *Staphylococcus aureus* septicemia ([@bib17]). This acquired resistance does not rely on T/B lymphocytes or natural killer (NK) cells but occurs in a myeloid-dependent manner ([@bib12], [@bib30]).

The C-type lectin receptor Dectin-1 is critical for *Candida albicans* or β-glucan sensing, leading to immune training of monocytes ([@bib30]). These primed macrophages show heightened production of proinflammatory cytokines to a wide variety of insults ([@bib22], [@bib30]). Dectin-1-mediated training relies on activation of the PI3K (phosphoinositide 3-kinase)/mTOR (mammalian target of rapamycin) pathway ([@bib12]). PI3K-induced Akt signaling is tightly regulated by phosphoinositide phosphatases, which counterbalance PI3K activity ([@bib18]). Among those phosphatases, the hematopoietic-restricted SHIP-1 (SH2-containing inositol 5′-phosphatase 1) ([@bib24]) is of particular interest, as we showed that it binds to the intracellular tail of Dectin-1 receptor in granulocyte-macrophage colony-stimulating factor (GM-CSF) bone marrow-derived cells ([@bib9]).

Because *Candida albicans*-induced trained immunity relies on Dectin-1 and PI3K signaling, and SHIP-1 couples to Dectin-1 and counteracts PI3K function, we postulated that SHIP-1 targeting could modulate trained immunity triggered by Dectin-1. Our results indicate that SHIP-1 has a regulatory role in β-glucan-induced training, affecting all hallmarks involved in that process. Moreover, *in vivo* SHIP-1 deficiency in the myeloid compartment improves protection conferred by trained immunity. Notably, enhanced proinflammatory cytokine production and better protection was also achieved by pharmacological SHIP-1 inhibition in both mice and human peripheral blood mononuclear cells (PBMCs), providing a potential therapeutic approach to boost trained immunity.

Results {#sec2}
=======

SHIP-1 Deletion Boosts β-Glucan-Induced Trained Immunity in Macrophages {#sec2.1}
-----------------------------------------------------------------------

Dectin-1 sensing of β-glucan induces trained immunity in myeloid cells, including PBMCs ([@bib22]) or bone marrow-derived macrophages (BMDMs) ([@bib34]). We initially stimulated BMDMs with purified particulate β-glucan from *S. cerevisiae*, a well-known ligand for Dectin-1 ([@bib31]). SHIP-1 basal expression in BMDMs was further induced after 1 day of β-glucan stimulation ([Figure 1](#fig1){ref-type="fig"}A). To study the potential involvement of SHIP-1 in Dectin-1-triggered trained immunity, we generated BMDMs from wild-type (WT) mice or mice bearing a myeloid-specific deletion of SHIP-1 in the myeloid compartment (LysMΔSHIP-1) ([@bib13]) ([Figure 1](#fig1){ref-type="fig"}B). Next, we adapted the proposed *in vitro* long-term scheme of trained immunity ([@bib30]) to IFN-γ-primed BMDMs, evaluating whether training with β-glucan boosts cytokine production in response to lipopolysaccharide (LPS) ([Figure 1](#fig1){ref-type="fig"}C). Of note, as previously described ([@bib28]), IFN-γ priming was required to detect LPS-induced cytokines in BMDMs ([Figure S1](#mmc1){ref-type="supplementary-material"}A), regardless of the induction of training. Surface expression of the receptors involved in β-glucan (Dectin-1; [Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}B) and LPS (TLR4; [Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}C) recognition were comparable between WT and LysMΔSHIP-1 BMDMs. We found that β-glucan-induced training resulted in increased cell viability in WT BMDMs ([Figure S2](#mmc1){ref-type="supplementary-material"}), concurring with previous results ([@bib7], [@bib19]). Non-trained SHIP-1-deficient BMDMs showed higher viability than their WT counterparts, but the relative cell number after β-glucan training was similar between genotypes ([Figure S2](#mmc1){ref-type="supplementary-material"}). To ensure the analysis of cell-intrinsic responses as described ([@bib7]), cytokine production was normalized to the relative cell number present in each treatment.Figure 1SHIP-1 Deletion Boosts β-Glucan-Induced Trained Immunity in Macrophages(A) SHIP-1 expression by WB, normalized to β-actin, in bone marrow-derived macrophages (BMDMs) exposed (+) or not (−) to β-glucan (whole glucan particles) for the indicated time. Representative experiment of three performed.(B) SHIP-1 protein expression in BMDMs. Representative experiment of six performed.(C) Trained immunity *in vitro* model in mouse BMDMs. See also [Figure S1](#mmc1){ref-type="supplementary-material"}A.(D and E) Dectin-1 expression in BMDMs before β-glucan stimulation (D) or TLR4 expression both under non-trained (left) or β-glucan-primed (right) conditions, just before LPS stimulation (E), according to [Figure 1](#fig1){ref-type="fig"}C. FACS histograms representative of four independent experiments. See also [Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C.(F) BMDMs were stimulated (+) or not (−) with β-glucan or LPS, and IL-1β (left), IL-6 (middle), and TNFα production (right) was analyzed in supernatants according to [Figure 1](#fig1){ref-type="fig"}C.See also [Figure S2](#mmc1){ref-type="supplementary-material"}. Independent experiments (N = 4 or 5) are shown. ^∗^p \< 0.05 and ^∗∗^p \< 0.01, paired Student's t test comparing wild-type (WT) and LysMΔSHIP-1. \#p \< 0.05, paired Student's t test comparing stimulated or not with β-glucan within the same genotype.

Pre-incubation of WT BMDMs with β-glucan prompted a greater production of IL-1β and TNFα in response to LPS ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}A), reproducing trained immunity ([@bib30]). Notably, β-glucan-trained LysMΔSHIP-1 BMDMs showed an increased production of these trained immunity-associated cytokines compared with trained WT BMDMs ([Figure 1](#fig1){ref-type="fig"}F). Conversely, IL-6 was not induced following training or in the absence of SHIP-1 in this setting ([Figure 1](#fig1){ref-type="fig"}F). Of note, SHIP-1 deletion did not affect any of these inflammatory responses under non-trained conditions. These data indicate that SHIP-1 modulates the extent of LPS-induced proinflammatory cytokine production specifically during β-glucan training.

SHIP-1 Regulates Molecular and Metabolic Hallmarks of Trained Immunity {#sec2.2}
----------------------------------------------------------------------

We tested whether the boost in β-glucan training in the absence of SHIP-1 was accompanied by regulation of key hallmarks involved in the process. Regarding the molecular pathway, Akt was phosphorylated in response to β-glucan in a time-dependent manner in WT BMDMs ([Figure 2](#fig2){ref-type="fig"}A, left, and [Figure S3](#mmc1){ref-type="supplementary-material"}A), concurring with previous results ([@bib12]). Notably, LysMΔSHIP-1 BMDMs showed significantly increased and sustained Akt phosphorylation upon β-glucan stimulation ([Figure 2](#fig2){ref-type="fig"}A, left, and [Figure S3](#mmc1){ref-type="supplementary-material"}A). The analysis of mTOR targets, S6 and 4EBP1, also revealed a maintained and significantly increased phosphorylation during the treatment with β-glucan in SHIP-1-deficient BMDMs ([Figure 2](#fig2){ref-type="fig"}A, right, and [Figure S3](#mmc1){ref-type="supplementary-material"}B). Of note, a basal activation of the Akt pathway occurs in LysMΔSHIP-1 BMDMs. This is consistent with previous results in which the absence of SHIP-1 was associated with Akt overactivation and survival advantage ([@bib1], [@bib36]), which would concur with our results in non-trained BMDMs ([Figure S2](#mmc1){ref-type="supplementary-material"}).Figure 2SHIP-1 Regulates Molecular and Metabolic Hallmarks of Trained Immunity(A) BMDMs were exposed to β-glucan for the indicated time, and phospho-Akt, Akt, phospho-S6, phospho-4EBP1, and β-actin were analyzed by WB. Representative experiment of five performed. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.(B--E) BMDMs were left untreated (dashed lines) or treated for 1 day with β-glucan (solid lines), washed, rested for 3 days, and re-plated in equal numbers for determination of extracellular acidification rate (ECAR) in a glycolysis stress test upon sequential addition of glucose, oligomycin, and 2-deoxyglucose (2DG) as indicated (B). Analysis of basal glycolysis (C), maximal glycolysis (D), and glycolytic reserve (E). See also [Figure S4](#mmc1){ref-type="supplementary-material"}. Mean ± SEM (B) or individual data (C--E) of five independent cultures are shown.(F) BMDMs were trained (+) or not (−) with β-glucan for 1 day, washed, and rested for 4 days and chromatin immunoprecipitation (ChIP) against H3K4me3 was performed in which enrichment on the TNFα promoter was analyzed using qPCR. Mean ± SEM of five independent experiments is shown.(G and H) BMDMs were incubated (+) or not (−) with the methyltransferase inhibitor 5′-deoxy-5′-(methylthio)adenosine (MTA), the histone demethylase inhibitor pargyline (G), the histone deacetylase activator resveratrol, or the histone acetyltransferase inhibitor EGCG (H) for 30 min before β-glucan training and after wash-out. TNFα production was analyzed in supernatants after LPS stimulation according to [Figure 1](#fig1){ref-type="fig"}C. Individual data corresponding to three (G) or four (H) independent experiments are shown.In (C)--(H), ^∗^p \< 0.05 and ^∗∗^p \< 0.01, paired Student's t test comparing WT and LysMΔSHIP-1. In (C)--(F), \#p \< 0.05, paired Student's t test comparing stimulated or not with β-glucan within the same genotype.

Next, we measured the extracellular acidification rate (ECAR) in β-glucan-trained BMDMs in a glycolysis stress test prior to LPS stimulation ([Figure 2](#fig2){ref-type="fig"}B). Training with β-glucan for 5 days increased ECAR in WT BMDMs, a metabolic shift that was significantly boosted in trained SHIP-1-deficient BMDMs ([Figure 2](#fig2){ref-type="fig"}B), as reflected by enhanced basal ([Figure 2](#fig2){ref-type="fig"}C) and maximal ([Figure 2](#fig2){ref-type="fig"}D) glycolysis, together with a higher glycolytic reserve ([Figure 2](#fig2){ref-type="fig"}E). Increase in glycolytic reserve is the first metabolic signature associated with SHIP-1-deficient BMDMs upon β-glucan training ([Figure S4](#mmc1){ref-type="supplementary-material"}). Consistent with data on signaling pathway activation ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}), basal enhanced glycolysis was found in LysMΔSHIP-1 BMDMs ([Figures 2](#fig2){ref-type="fig"}C--2E and [S4](#mmc1){ref-type="supplementary-material"}), although it did not result in higher cytokine production unless β-glucan-induced training was established ([Figure 1](#fig1){ref-type="fig"}F). These results suggest that SHIP-1 controls the extent of the glycolytic switch. Therefore, SHIP-1 deficiency may promote a pro-glycolytic state that could boost inflammatory response upon β-glucan-trained conditions.

To assess whether SHIP-1 could affect epigenetic reprogramming induced by β-glucan, we tested the presence of the activating histone 3 Lys 4 trimethylation (H3K4me3) ([@bib12], [@bib30]). Chromatin immunoprecipitation (ChIP) analysis showed that H3K4me3 was specifically enriched by β-glucan training at TNFα promoter in WT BMDMs and further augmented in trained SHIP-1-deficient macrophages ([Figure 2](#fig2){ref-type="fig"}F), concurring with final enhanced TNFα production ([Figure 1](#fig1){ref-type="fig"}F). Moreover, inhibition of histone methyltransferases using 5′-deoxy-5′-(methylthio)adenosine (MTA) ([@bib30]) abolished TNFα overproduction in the absence of SHIP-1 upon training, whereas the histone demethylase inhibitor pargyline ([@bib30]) did not have any effect ([Figure 2](#fig2){ref-type="fig"}G). Considering that β-glucan-induced training relies also on histone acetylation, training in the presence of the histone deacetylase activator resveratrol ([@bib12]) or the histone acetyltransferase inhibitor EGCG ([@bib23]) inhibited the enhanced TNFα produced by trained SHIP-1-deficient macrophages ([Figure 2](#fig2){ref-type="fig"}H). These results highlight SHIP-1 as a regulator of trained immunity by dampening the Akt/mTOR molecular pathway and the glycolytic switch and relying on the epigenetic reprogramming induced by β-glucan.

Myeloid-Specific Deletion of SHIP-1 Improves Trained Immunity *In Vivo* {#sec2.3}
-----------------------------------------------------------------------

The generation of trained immunity *in vivo* leads to cross-protection against diverse secondary infections ([@bib29]). Signaling through PI3K is the canonical molecular pathway implicated in the development of these trained responses ([@bib2], [@bib12]). To test the role of myeloid SHIP-1 in cytokine production under β-glucan training *in vivo*, WT and LysMΔSHIP-1 mice were challenged with LPS after training with β-glucan ([@bib12]), and serum cytokines were measured ([Figure 3](#fig3){ref-type="fig"}A). LPS-induced levels of IL-6 and TNFα were increased in sera from WT mice upon β-glucan pre-treatment ([Figure 3](#fig3){ref-type="fig"}B), indicative of the generation of a trained response ([@bib30]). Notably, serum levels of IL-1β, IL-6, and TNFα were further increased in LysMΔSHIP-1 trained mice compared with trained WT mice ([Figure 3](#fig3){ref-type="fig"}B), supporting the regulatory role of SHIP-1 upon β-glucan training also *in vivo*.Figure 3Myeloid-Specific Deletion of SHIP-1 Improves Trained Immunity *In Vivo*(A) *In vivo* model of training by two intraperitoneal (i.p.) β-glucan injections and secondary i.p. LPS challenge for measuring serum cytokines.(B) Mice were treated according to [Figure 3](#fig3){ref-type="fig"}A. Serum was collected after 60 min (TNFα) or 90 min (IL-1β and IL-6) of LPS challenge, and cytokines were analyzed.(C) *In vivo* model of training as in (A) but with secondary *Candida albicans* lethal infection.(D) Survival curve according to [Figure 3](#fig3){ref-type="fig"}C.(E) *In vivo* model of training by a systemic infection with a low dose of *C. albicans* followed by a secondary lethal challenge with the same pathogen.(F) Survival curve according to [Figure 3](#fig3){ref-type="fig"}E.(G and H) Renal cytokines on day 2 post-infection (p.i.) (G) and kidney fungal burden (H) at indicated time points p.i. were evaluated in trained mice, following model in [Figure 3](#fig3){ref-type="fig"}E.In (B), (G), and (H), single dots correspond to individual mice. Mean ± SEM of two (B and H) or three (G) pooled experiments is shown, including at least 5 mice per condition. ^∗^p \< 0.05 and ^∗∗^p \< 0.01, unpaired Student's t test comparing WT and LysMΔSHIP-1. \#p \< 0.05, unpaired Student's t test comparing the same genotype stimulated or not with β-glucan. In (D) and (F), a pool of two experiments is shown, including between 6 and 16 mice per group as indicated. ^∗∗^p \< 0.01, log rank test between WT and LysMΔSHIP-1 mice. \#p \< 0.05, log rank test comparing trained or not with β-glucan (D) or *C. albicans* (F) within the same genotype.

Protective response against lethal systemic *Candida albicans* infection by trained immunity relies on monocytes and macrophages ([@bib30]). After training with β-glucan, WT and LysMΔSHIP-1 mice were intravenously infected with a lethal dose of the clinical isolate *C. albicans* SC5314 ([Figure 3](#fig3){ref-type="fig"}C). Both WT and LysMΔSHIP-1 non-trained mice rapidly succumbed upon these infectious conditions ([Figure 3](#fig3){ref-type="fig"}D, dashed lines), indicating that SHIP-1 expression in the myeloid compartment is redundant for the primary response to lethal candidiasis. The protective effect of β-glucan administration against a lethal *C. albicans* infection was significantly improved in LysMΔSHIP-1 mice compared with WT littermates ([Figure 3](#fig3){ref-type="fig"}D, solid lines).

As trained immunity can be defined as a protection mechanism from secondary lethal *C. albicans* infection induced by a nonlethal encounter with the same pathogen ([@bib30]), we trained mice with a low dose of *C. albicans* followed by a lethal dose of the fungus ([Figure 3](#fig3){ref-type="fig"}E). Again, the training stimulus enlarged the survival time of WT mice and LysMΔSHIP-1 trained mice were more resistant than WT to lethal systemic candidiasis ([Figure 3](#fig3){ref-type="fig"}F, solid lines). Notably, we observed enhanced production of IL-1β and TNFα in *Candida* lethally infected kidneys from LysMΔSHIP-1 trained mice ([Figure 3](#fig3){ref-type="fig"}G), together with a decreased renal fungal burden ([Figure 3](#fig3){ref-type="fig"}H). These data indicate that SHIP-1 deficiency in myeloid cells enhances β-glucan- and *Candida*-induced trained immunity *in vivo*, improving the response to pathogen-specific or heterologous challenges.

Pharmacological Inhibition of SHIP-1 Enhances Trained Immunity {#sec2.4}
--------------------------------------------------------------

The relevance of the PI3K pathway in distinct pathologies has promoted the development of chemical SHIP-1 phosphatase inhibitors such as 3α-aminocholestane (3AC; SHIPi) ([@bib10]). We thus tested 3AC as a potential tool to boost trained immunity. BMDMs were trained with β-glucan in presence of different doses of 3AC (half maximal inhibitory concentration \[IC~50~\] = 13.5 μM; [@bib11]), and LPS-induced TNFα was measured ([Figure 4](#fig4){ref-type="fig"}A). Upon β-glucan training, SHIP-1 inhibition boosted TNFα production in a dose-dependent manner ([Figure 4](#fig4){ref-type="fig"}B).Figure 4Pharmacological Inhibition of SHIP-1 Enhances Trained Immunity(A) *In vitro* experimental model applied to mouse BMDMs, indicating when the SHIP-1 inhibitor (SHIPi) 3α-aminocholestane (3AC) was added.(B) Mouse BMDMs were incubated with the SHIPi at the indicated concentrations. TNFα production was analyzed in supernatants of β-glucan-trained cells after LPS stimulation according to [Figure 4](#fig4){ref-type="fig"}A. Mean + SEM of four independent experiments is shown. ^∗∗^p \< 0.01, paired Student's t test between SHIPi-treated and non-treated cells.(C) *In vivo* model of training by a systemic infection with a low dose of *Candida albicans* in the presence of SHIPi followed by a second lethal challenge with the same pathogen. When indicated, the inhibitor was administered intraperitoneally.(D) Survival curve of 0.3% hydroxypropylcellulose (control) or SHIPi-treated mice according to [Figure 4](#fig4){ref-type="fig"}C. A pool of two experiments is shown, including between 10 and 19 mice per group as indicated. ^∗∗^p \< 0.01, log rank test between trained control and SHIPi-treated. \#p \< 0.05, log rank test comparing trained or not with *C. albicans* within the same treatment.(E) *In vitro* experimental model applied to human peripheral blood mononuclear cells (PBMCs) indicating when SHIPi was added.(F) IL-1β, IL-6, and TNFα production was analyzed in supernatants of β-glucan-trained human PBMCs after LPS stimulation according to [Figure 4](#fig4){ref-type="fig"}E. Samples from seven independent donors are shown. ^∗^p \< 0.05, paired Student's t test.

To analyze the effect of 3AC SHIPi under *in vivo* infectious conditions, mice were administered SHIPi twice on consecutive days following the published regimen ([@bib20]), and coincident with the second day of 3AC administration, mice were trained with a low dose of *C. albicans*. Seven days later, mice were lethally infected with the same fungus ([Figure 4](#fig4){ref-type="fig"}C). Inhibition of SHIP-1 did not affect the survival of non-trained mice ([Figure 4](#fig4){ref-type="fig"}D, dashed lines) but improved the survival of *Candida*-trained mice ([Figure 4](#fig4){ref-type="fig"}D, solid lines).

To further explore the potential relevance of the use of 3AC SHIPi, we trained human PBMCs in the presence of SHIPi, rested and stimulated with LPS, and cytokine production was measured ([Figure 4](#fig4){ref-type="fig"}E). This scheme mirrors the stimulation pattern proposed for human PBMCs elsewhere ([@bib30]). Importantly, SHIP-1 inhibition boosted IL-1β, IL-6, and TNFα production in these β-glucan-trained human PBMCs ([Figure 4](#fig4){ref-type="fig"}F). Thus, our data indicate that SHIP-1 can be targeted with pharmacological inhibitors in both mice and human cells to boost trained immunity.

Discussion {#sec3}
==========

Herein, we define SHIP-1 in myeloid cells as a target to improve trained immunity. Additionally, we provide a pharmacological approach, the SHIP-1 inhibitor 3AC, improving training-induced resistance to *Candida* infection and trained immunity in human PBMCs. Because modulation of myeloid progenitors in the bone marrow is an integral component of trained immunity ([@bib27]), and 3AC administration expands the hematopoietic stem cell compartment ([@bib11]), SHIP-1 inhibition could also influence this compartment. Although *Candida*-induced training and the primary response to the fungus are T/B cell independent ([@bib6], [@bib30]), systemic inhibition of SHIP-1 can also influence NK and T cells ([@bib20]), and we cannot rule out indirect effects on non-myeloid cells.

We show that SHIP-1 inhibition potentiates the canonical PI3K/Akt activation pathway, which also mediates trained immunity in response to other stimuli such as the bacillus Calmette-Guérin (BCG) vaccine ([@bib2]). SHIP-1 inhibition could represent a broad strategy to boost trained immunity. Indeed, SHIP-1 displays an inhibitory function in NOD2 signaling ([@bib14]), the BCG-mediated trained immunity pathway ([@bib25]). Considering that BCG vaccination confers cross-protection to human viral infections ([@bib5]), SHIP-1 inhibitor could improve the protective effect of BCG.

Enhanced trained immunity could raise as an important host defense mechanism against infections or sepsis ([@bib29]). However, because diverse endogenous danger signals from injured tissues can trigger innate immune memory hallmarks ([@bib16]), caution is needed regarding the potential deleterious function of boosting trained immunity in diseases characterized by excessive inflammation. This notion could apply to atherosclerosis ([@bib26]), cardiovascular events ([@bib21]), gout ([@bib15]), and a variety of autoimmune diseases and autoinflammatory disorders such as rheumatoid arthritis, systemic lupus erythematosus, and hyper-IgD syndrome ([@bib4]), in which monocytes and macrophages share a detrimental trained immunity-like phenotype. Similarly, boosting microglia-dependent training ([@bib35]) through SHIP-1 inhibition could be detrimental for neurological disorders and stroke. Under these settings, SHIP-1 activators such as AQX-1125 ([@bib33]) could be potentially used to ameliorate an excessive and detrimental activation of trained immunity.

In conclusion, although studies on trained immunity have focused on the characterization of this phenomenon, strategies to enhance trained immunity deserve further investigation. Our data indicate that the trained immunity process can be boosted by targeting SHIP-1 in myeloid cells. Moreover, SHIP-1 inhibitors could be proposed as potential pharmacological tools to improve trained immunity in clinical settings in which enhancement of inflammatory responses is beneficial.

Experimental Procedures {#sec4}
=======================

Mice and Human Samples {#sec4.1}
----------------------

Mice were bred at Centro Nacional de Investigaciones Cardiovasculares (CNIC) under specific pathogen-free conditions. WT C57BL/6J mice were used for SHIP-1 inhibition experiments. LysM^+/+^SHIP-1^flox/flox^ (WT) and LysM^Cre/+^SHIP-1^flox/flox^ (LysMΔSHIP-1) ([@bib13]) were kept as littermates. Experiments were conducted with 8- to 12-week-old age-matched mice (regardless of gender). Experiments were approved by the animal ethics committee at CNIC and conformed to Spanish law under Real Decreto 1201/2005. Animal procedures were also performed in accordance to European Union (EU) Directive 2010/63EU and Recommendation 2007/526/EC.

Buffy coats from healthy volunteers were obtained from the Andalusian Biobank after ethical approval was obtained from the local Instituto de Salud Carlos III (ISCIII) Research Ethics Committee (PI 36_2017).

Trained Immunity *In Vitro* Models {#sec4.2}
----------------------------------

### BMDMs {#sec4.2.1}

BMDMs (10^5^) were plated in 96-well plates (200 μL final volume; Corning) and stimulated with R10 or 100 μg/mL β-glucan (whole glucan particles, Biothera) for 24 hr. Then, cells were washed and rested 3 days in culture medium. On day 4, unless indicated, BMDMs were washed again and primed with 25 ng/mL IFN-γ (BD Biosciences) for 24 hr. On day 5, a final wash was performed, and cells were stimulated with R10 or 1 μg/mL standard *Escherichia coli* LPS (EK; Invivogen). To measure IL-1β production, following 4 hr of LPS challenge, cells were further stimulated for 2 hr with 5 mM ATP (Sigma-Aldrich), needed for inflammasome activation and pro-IL-1β processing ([@bib32]), and supernatants were harvested for ELISA assay. For TNFα and IL-6, after 24 hr of LPS stimulation, supernatants were collected for ELISA.

When required, BMDMs were pre-incubated for 30 min prior to β-glucan stimulation with 500 μM 5′-deoxy-5′-(methylthio)adenosine (MTA), 6 μM pargyline, 50 μM resveratrol, and 50 μM (-)-epigallocatechin-3-gallate (EGCG) (all from Sigma-Aldrich). SHIP-1 inhibitor (SHIPi; 3AC; Calbiochem) was also used at the indicated doses on β-glucan-trained BMDMs (toxic for non-trained cells). Inhibitors were also added in the first wash-out, before the resting period.

To assess receptor expression and cell viability, 6 × 10^5^ BMDMs were plated in non-treated 24-well plates (1,200 μL final volume; Corning) and followed the training scheme described above. Dectin-1 expression was evaluated on day 0 prior to β-glucan addition. Cell viability and TLR4 expression were assessed on day 5 before LPS stimulation. At indicated times, cells were collected in PBS/EDTA and stained on ice-cold fluorescence-activated cell sorting (FACS) buffer (PBS/EDTA plus 3% fetal bovine serum \[FBS\]) for flow cytometry analysis.

For western blotting (WB) assays and ChIP analysis, 3 × 10^6^ BMDMs were plated in six-well plates (3 mL final volume; Corning) and stimulated with R10 or 200 μg/mL β-glucan (to maintain mass/cell ratio) for given times. ChIP was performed on day 5, without IFN-γ priming, as detailed below.

To address metabolic status, 3 × 10^6^ BMDMs were plated in non-treated 6-well plates (3 mL final volume; Corning) and followed the training scheme described above but with 200 μg/mL β-glucan (to maintain mass/cell ratio). On day 4, without IFN-γ priming, cells were detached in PBS/EDTA, plated at 10^5^ cells/well, and rested overnight in R10 prior to the Seahorse XF glycolysis stress test (Agilent Technologies). When glycolytic metabolism was evaluated after overnight stimulation with β-glucan, BMDMs (10^5^) were directly plated in 96-well Seahorse cell culture plates (200 μL final volume; Agilent Technologies) and stimulated with R10 or 100 μg/mL β-glucan the following day.

### PBMCs {#sec4.2.2}

Total PBMCs (5 × 10^5^) were plated in 96-well plates (200 μL final volume) and stimulated with 100 μg/mL β-glucan for 24 hr. Then cells were washed and rested for 6 days in culture medium. On day 7, PBMCs were stimulated with 1 μg/mL LPS (EK). After 24 hr, supernatants were collected for IL-1β, IL-6, and TNFα measurement by ELISA. When required, β-glucan-trained PBMCs were pre-incubated for 30 min with 10 μM 3AC (toxic for non-trained cells). Inhibitor was also added together with the first wash-out, before the resting period.

To assess cell viability, 3 × 10^6^ total PBMCs were plated in 24-well plates (1,200 μL final volume; Corning) and followed the training scheme described here. On day 7, prior to LPS stimulation, cells were collected in PBS/EDTA and stained on ice-cold FACS buffer for flow cytometry analysis.

For normalization of cytokine production, the fold cell number in each condition was calculated as follows: live cell number/live cell number in average non-trained WT, according to [Figure S2](#mmc1){ref-type="supplementary-material"}. In case of SHIP-1 inhibition experiments, non-treated cells were used as reference. Thus, cytokine production was normalized per cell number as (absolute cytokine value/fold cell number) in each condition.

*In Vivo* Models {#sec4.3}
----------------

Mice were trained with either two intraperitoneal (i.p.) injections of 1 mg β-glucan particles on days −7 and −4 or 2 × 10^4^ *Candida albicans* intravenously (i.v.) on day −7. Sterile PBS was used as control. One week later, mice were challenged with 5 μg *E. coli* LPS (serotype O55:B5; Sigma-Aldrich) i.p., and blood was collected 60 min later to assess serum TNFα (Mouse TNFα DuoSet; R&D Systems) or 90 min later to evaluate serum IL-1β and IL-6. Alternatively, mice were lethally infected with 2 × 10^6^ *C. albicans* i.v. and monitored daily for weight, general health, and survival, following institutional guidance. For qPCR analysis of renal cytokines, RNA was purified from whole kidneys on day 2 post-secondary infection (p.i.). Kidney fungal burden at indicated time points p.i. was determined by plating organ homogenates obtained mechanically over 70 μm cell strainers (BD Biosciences) after slicing the tissue, in serial dilutions on YPD agar plates; colony-forming units (CFUs) were counted after growth at 30°C for 48 hr, and data are shown as CFUs in total kidney. When required, mice were i.p. treated with 0.11 mg 3AC on days −8 and −7. 3AC was diluted in PBS 0.3% hydroxypropylcellulose (Sigma-Aldrich), used as control.

Quantification and Statistical Analysis {#sec4.4}
---------------------------------------

The statistical analysis was performed using Prism (GraphPad Software). Unless specified, statistical significance for comparison between two sample groups with a normal distribution (Shapiro-Wilk test for normality) was determined using two-tailed paired or unpaired Student's t test. When groups were too small to estimate normality, a Gaussian distribution was assumed. Comparison of survival curves was carried out using the log rank (Mantel-Cox) test. Outliers were identified by means of Tukey's range test. Differences were considered significant at p \< 0.05 as indicated. Except when specified, only significant differences are shown. As indicated in figure legends, either a representative experiment or a pool is shown, and the number of repetitions of each experiment and number of experimental units (either cultures or mice) is indicated. *In vitro* experiments are shown as a pool of experiments, in which linked WT-LysMΔSHIP-1 dots represent independent cultures that were processed within the same experiment. In this way, an internal comparison between genotypes can be visually done. Different conditions within the same genotype in a particular experiment, although not connected by a matter of clarity, were also pair-analyzed, and statistically significant differences are indicated by pound signs (\#).
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